Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

The prevalence of ultrasound signs of fatty hepatosis and comorbidities in hospital patients in Kyrgyzstan

The prevalence of ultrasound signs of fatty hepatosis and comorbidities in hospital patients in Kyrgyzstan
Полный текст  

Abstract

Introduction. Ultrasound, as a non-invasive and readily available tool, plays an important role in the diagnosis of non-alcoholic fatty liver disease (NAFLD). The prevalence of NAFLD has not been previously studied in Kyrgyzstan. Knowing the incidence of fatty liver infiltration in hospitalized patients is necessary for active diagnosis and timely prevention of complications of NAFLD.The aim of the study- to determine the prevalence of fatty liver and associated pathologies of the internal organs of the abdominal cavity in patients undergoing inpatient treatment. Material and methods. A total of 6,720 visitors to the City Clinical Hospital No. 1 in Bishkek were examined. The mean age was 45.9 years. Among them, women - 53.8%, men - 46.2%. The inclusion criteria for the examined groups were: age from 18 to 92 years; consent of the patient to participate in the study. Exclusion criteria: the presence of severe concomitant somatic, oncological, hematological and mental diseases; refusal to participate in the study. The control group consisted of individuals without ultrasound signs of fatty liver (2466 people in total). The comparison group included 4254 people with ultrasound signs characteristic of fatty liver. In each study group, two age categories were considered: older and younger than 45 years. All subjects underwent an ultrasound examination of the abdominal organs. The results were analyzed using the SPSS 16.0 statistical software package for Windows. Results. It was found that among patients of a multidisciplinary hospital, the prevalence of signs of fatty liver is 63.3%, among people under 45 years old - 43%, and in people over 45 years old - 79.1%. Among the comorbid pathology in persons with fatty liver, signs of chronic cholecystitis, pancreatitis, cholelithiasis and pyelonephritis were statistically significant. More than 60% of the younger age group with fatty liver have signs of chronic pancreatitis versus 36.2% without fatty infiltration. In older people, it increases to 81% and 72%, respectively. Among patients under 45 years of age, I degree of fatty liver prevailed. In patients older than 45 years, grades II and III were statistically significant. A statistically significant average correlation of fatty liver with pancreatitis was found. A weak direct correlation of fatty liver with chronic cholecystitis and pyelonephritis was also found. Conclusions. High prevalence of ultrasound signs of fatty infiltration of the liver (79.1%) among examined patients over 45 years of age who are hospitalized in a multidisciplinary hospital, and the prevalence of signs of chronic cholecystitis, pancreatitis, cholelithiasis and pyelonephritis highlights the need for careful diagnosis of liver diseases in order to prevent complications such as cirrhosis of the liver and hepatocellular carcinoma.

About the authors

Токтогулова Нургуль Асылбековна, к.м.н., доцент, зав.кафедрой терапии №1 Кыргызско-Российского Славянского университета имени Б.Н. Ельцина, Бишкек, Кыргызская Республика
Сыдыкбекова Айсулуу Асановна, Врач УЗИ Городской клинической больницы №1, Бишкек, Кыргызская Республика
Сатаров Умиджон Абдихапарович, преподаватель Международного университета Кыргызстана, Бишкек, Кыргызская Республика

Toktogulova Nurgul Asylbekovna, Ph.D., Associate Professor, Head of the Department of Therapy No. 1 of the Kyrgyz-Russian Slavic University named after B.N. Yeltsin, Bishkek, Kyrgyz Republic
Sydykbekova Aisuluu Asanovna, Ultrasound Doctor, City Clinical Hospital No. 1, Bishkek, Kyrgyz Republic
Satarov Umidjon Abdikhaparovich, lecturer at the International University of Kyrgyzstan, Bishkek, Kyrgyz Republic

Токтогулова Нургүл Асылбековна, медицина илимдеринин кандидаты, доцент, Б.Н. Ельцин атындагы Кыргыз-Орус Славян университетинин №1 терапиясынын кафедрасынын башчысы, Бишкек, Кыргыз Республикасы
Сыдыкбекова Айсулуу Асановна, №1 шаардык клиникалык ооруканасынын УЗИ дарыгери, Бишкек шаары, Кыргыз Республикасы
Сатаров Умиджон Абдихапарович, Кыргызстан Эл аралык университетинин окутуучусу, Бишкек, Кыргыз Республикасы

References

1. Garteiser P. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates //JHEP Reports. 2021. Т. 3. №. 6. С. 100381.
2. Popa A.et al.Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastographyas reference in patients with chronic liver diseases //Ultrasound in Medicine & Biology. 2021. Т. 47. №. 7. С. 1692-1703.
3. Ballestri S. et al. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies //Metabolism and Target Organ Damage. 2021. Т. 1. №. 7.
4. Rau M., Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease–from ongoing clinical trials to future therapy //Expert Review of Clinical Pharmacology. 2021. Т. 14. №. 3. С. 333-340.
5. Tutunchi H. et al. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults BMC Research Notes. 2020. Т. 13. №. 1. С. 1-5.
6. Lee S. et al. Visceral adiposity as a risk factor for lean non‐alcoholic fatty liver disease in potential living liver donors //Journal of Gastroenterology and Hepatology. 2021. Т. 36. №. 11. С. 3212-3218.
7. Harrison S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort //Journal of hepatology. 2021. Т. 75. №. 2. С. 284-291.
8. Jung C. H. et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis //Endocrinology and Metabolism. 2020. Т. 35. №. 1. С. 165-176.
9. Silva-Santisteban A. et al. EUS imaging for the diagnosis of nonalcoholic fatty liver disease //Gastrointestinal Endoscopy. 2022. Т. 95. №. 4. С. 711-716.
10. Méndez-Sánchez N., Díaz-Orozco L. E. International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) //Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021. Т. 27. С. e933860-1.

1. Garteiser P. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates //JHEP Reports. 2021. Т. 3. №. 6. С. 100381.
2. Popa A.et al.Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastographyas reference in patients with chronic liver diseases //Ultrasound in Medicine & Biology. 2021. Т. 47. №. 7. С. 1692-1703.
3. Ballestri S. et al. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies //Metabolism and Target Organ Damage. 2021. Т. 1. №. 7.
4. Rau M., Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease–from ongoing clinical trials to future therapy //Expert Review of Clinical Pharmacology. 2021. Т. 14. №. 3. С. 333-340.
5. Tutunchi H. et al. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults BMC Research Notes. 2020. Т. 13. №. 1. С. 1-5.
6. Lee S. et al. Visceral adiposity as a risk factor for lean non‐alcoholic fatty liver disease in potential living liver donors //Journal of Gastroenterology and Hepatology. 2021. Т. 36. №. 11. С. 3212-3218.
7. Harrison S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort //Journal of hepatology. 2021. Т. 75. №. 2. С. 284-291.
8. Jung C. H. et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis //Endocrinology and Metabolism. 2020. Т. 35. №. 1. С. 165-176.
9. Silva-Santisteban A. et al. EUS imaging for the diagnosis of nonalcoholic fatty liver disease //Gastrointestinal Endoscopy. 2022. Т. 95. №. 4. С. 711-716.
10. Méndez-Sánchez N., Díaz-Orozco L. E. International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) //Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021. Т. 27. С. e933860-1.

1. Garteiser P. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates //JHEP Reports. 2021. Т. 3. №. 6. С. 100381.
2. Popa A.et al.Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastographyas reference in patients with chronic liver diseases //Ultrasound in Medicine & Biology. 2021. Т. 47. №. 7. С. 1692-1703.
3. Ballestri S. et al. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies //Metabolism and Target Organ Damage. 2021. Т. 1. №. 7.
4. Rau M., Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease–from ongoing clinical trials to future therapy //Expert Review of Clinical Pharmacology. 2021. Т. 14. №. 3. С. 333-340.
5. Tutunchi H. et al. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults BMC Research Notes. 2020. Т. 13. №. 1. С. 1-5.
6. Lee S. et al. Visceral adiposity as a risk factor for lean non‐alcoholic fatty liver disease in potential living liver donors //Journal of Gastroenterology and Hepatology. 2021. Т. 36. №. 11. С. 3212-3218.
7. Harrison S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort //Journal of hepatology. 2021. Т. 75. №. 2. С. 284-291.
8. Jung C. H. et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis //Endocrinology and Metabolism. 2020. Т. 35. №. 1. С. 165-176.
9. Silva-Santisteban A. et al. EUS imaging for the diagnosis of nonalcoholic fatty liver disease //Gastrointestinal Endoscopy. 2022. Т. 95. №. 4. С. 711-716.
10. Méndez-Sánchez N., Díaz-Orozco L. E. International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) //Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021. Т. 27. С. e933860-1.

Для цитирования

Токтогулова Н.А., Сыдыкбекова А.А., Сатаров У.А. Распространённость ультразвуковых признаков жирового гепатоза и сочетанных патологий у стационарных больных в Кыргызстане. Здравоохранение Кыргызстана 2022, № 4, с. 68-74. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68

For citation

Toktogulova N.A., Sydykbekova A.A., Satarov U.A.The prevalence of ultrasound signs of fatty hepatosis and comor
bidities in hospital patients in Kyrgyzstan. Health care of Kyrgyzstan 2022, No.4, pp. 68-74. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68

Цитата үчүн

Токтогулова Н.А., Сыдыкбекова А.А., Сатаров У.А. Кыргызстанда стационардагы бейтаптарда майлуу гепатоздун жана кошумча оорулардын УЗИ белгилеринин таралышы. Кыргызстандын саламаттык сактоо 2022, no 4, б. 68-74. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68

Authors Toktogulova N.A., Sydykbekova A.A., Satarov U.A.
Link doi.org https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68
Pages 68-74
Keywords non-alcoholic fatty liver disease, ultrasound, associated diseases
Russian
Об авторах

Токтогулова Нургуль Асылбековна, к.м.н., доцент, зав.кафедрой терапии №1 Кыргызско-Российского Славянского университета имени Б.Н. Ельцина, Бишкек, Кыргызская Республика
Сыдыкбекова Айсулуу Асановна, Врач УЗИ Городской клинической больницы №1, Бишкек, Кыргызская Республика
Сатаров Умиджон Абдихапарович, преподаватель Международного университета Кыргызстана, Бишкек, Кыргызская Республика

Полный текст

PDF (RUS)

Список литературы

1. Garteiser P. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates //JHEP Reports. 2021. Т. 3. №. 6. С. 100381.
2. Popa A.et al.Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastographyas reference in patients with chronic liver diseases //Ultrasound in Medicine & Biology. 2021. Т. 47. №. 7. С. 1692-1703.
3. Ballestri S. et al. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies //Metabolism and Target Organ Damage. 2021. Т. 1. №. 7.
4. Rau M., Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease–from ongoing clinical trials to future therapy //Expert Review of Clinical Pharmacology. 2021. Т. 14. №. 3. С. 333-340.
5. Tutunchi H. et al. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults BMC Research Notes. 2020. Т. 13. №. 1. С. 1-5.
6. Lee S. et al. Visceral adiposity as a risk factor for lean non‐alcoholic fatty liver disease in potential living liver donors //Journal of Gastroenterology and Hepatology. 2021. Т. 36. №. 11. С. 3212-3218.
7. Harrison S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort //Journal of hepatology. 2021. Т. 75. №. 2. С. 284-291.
8. Jung C. H. et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis //Endocrinology and Metabolism. 2020. Т. 35. №. 1. С. 165-176.
9. Silva-Santisteban A. et al. EUS imaging for the diagnosis of nonalcoholic fatty liver disease //Gastrointestinal Endoscopy. 2022. Т. 95. №. 4. С. 711-716.
10. Méndez-Sánchez N., Díaz-Orozco L. E. International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) //Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021. Т. 27. С. e933860-1.

Для цитирования

Токтогулова Н.А., Сыдыкбекова А.А., Сатаров У.А. Распространённость ультразвуковых признаков жирового гепатоза и сочетанных патологий у стационарных больных в Кыргызстане. Здравоохранение Кыргызстана 2022, № 4, с. 68-74. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68

English
About authors

Toktogulova Nurgul Asylbekovna, Ph.D., Associate Professor, Head of the Department of Therapy No. 1 of the Kyrgyz-Russian Slavic University named after B.N. Yeltsin, Bishkek, Kyrgyz Republic
Sydykbekova Aisuluu Asanovna, Ultrasound Doctor, City Clinical Hospital No. 1, Bishkek, Kyrgyz Republic
Satarov Umidjon Abdikhaparovich, lecturer at the International University of Kyrgyzstan, Bishkek, Kyrgyz Republic

References

1. Garteiser P. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates //JHEP Reports. 2021. Т. 3. №. 6. С. 100381.
2. Popa A.et al.Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastographyas reference in patients with chronic liver diseases //Ultrasound in Medicine & Biology. 2021. Т. 47. №. 7. С. 1692-1703.
3. Ballestri S. et al. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies //Metabolism and Target Organ Damage. 2021. Т. 1. №. 7.
4. Rau M., Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease–from ongoing clinical trials to future therapy //Expert Review of Clinical Pharmacology. 2021. Т. 14. №. 3. С. 333-340.
5. Tutunchi H. et al. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults BMC Research Notes. 2020. Т. 13. №. 1. С. 1-5.
6. Lee S. et al. Visceral adiposity as a risk factor for lean non‐alcoholic fatty liver disease in potential living liver donors //Journal of Gastroenterology and Hepatology. 2021. Т. 36. №. 11. С. 3212-3218.
7. Harrison S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort //Journal of hepatology. 2021. Т. 75. №. 2. С. 284-291.
8. Jung C. H. et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis //Endocrinology and Metabolism. 2020. Т. 35. №. 1. С. 165-176.
9. Silva-Santisteban A. et al. EUS imaging for the diagnosis of nonalcoholic fatty liver disease //Gastrointestinal Endoscopy. 2022. Т. 95. №. 4. С. 711-716.
10. Méndez-Sánchez N., Díaz-Orozco L. E. International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) //Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021. Т. 27. С. e933860-1.

For citation

Toktogulova N.A., Sydykbekova A.A., Satarov U.A.The prevalence of ultrasound signs of fatty hepatosis and comor
bidities in hospital patients in Kyrgyzstan. Health care of Kyrgyzstan 2022, No.4, pp. 68-74. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68

Kyrgyz
Авторлор жөнүндө

Токтогулова Нургүл Асылбековна, медицина илимдеринин кандидаты, доцент, Б.Н. Ельцин атындагы Кыргыз-Орус Славян университетинин №1 терапиясынын кафедрасынын башчысы, Бишкек, Кыргыз Республикасы
Сыдыкбекова Айсулуу Асановна, №1 шаардык клиникалык ооруканасынын УЗИ дарыгери, Бишкек шаары, Кыргыз Республикасы
Сатаров Умиджон Абдихапарович, Кыргызстан Эл аралык университетинин окутуучусу, Бишкек, Кыргыз Республикасы

Шилтемелер

1. Garteiser P. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates //JHEP Reports. 2021. Т. 3. №. 6. С. 100381.
2. Popa A.et al.Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastographyas reference in patients with chronic liver diseases //Ultrasound in Medicine & Biology. 2021. Т. 47. №. 7. С. 1692-1703.
3. Ballestri S. et al. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies //Metabolism and Target Organ Damage. 2021. Т. 1. №. 7.
4. Rau M., Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease–from ongoing clinical trials to future therapy //Expert Review of Clinical Pharmacology. 2021. Т. 14. №. 3. С. 333-340.
5. Tutunchi H. et al. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults BMC Research Notes. 2020. Т. 13. №. 1. С. 1-5.
6. Lee S. et al. Visceral adiposity as a risk factor for lean non‐alcoholic fatty liver disease in potential living liver donors //Journal of Gastroenterology and Hepatology. 2021. Т. 36. №. 11. С. 3212-3218.
7. Harrison S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort //Journal of hepatology. 2021. Т. 75. №. 2. С. 284-291.
8. Jung C. H. et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis //Endocrinology and Metabolism. 2020. Т. 35. №. 1. С. 165-176.
9. Silva-Santisteban A. et al. EUS imaging for the diagnosis of nonalcoholic fatty liver disease //Gastrointestinal Endoscopy. 2022. Т. 95. №. 4. С. 711-716.
10. Méndez-Sánchez N., Díaz-Orozco L. E. International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) //Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021. Т. 27. С. e933860-1.

Цитата үчүн

Токтогулова Н.А., Сыдыкбекова А.А., Сатаров У.А. Кыргызстанда стационардагы бейтаптарда майлуу гепатоздун жана кошумча оорулардын УЗИ белгилеринин таралышы. Кыргызстандын саламаттык сактоо 2022, no 4, б. 68-74. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68

Views: 2757
Copyright MAXXmarketing GmbH
JoomShopping Download & Support